Pakistan Stock Exchange (PSX) announced on Wednesday that BF Biosciences Limited has applied for listing on its Main Board.
The Initial Public Offering (IPO) will consist of 25 million ordinary shares, each with a par value of Rs. 3/-, utilizing the Book Building Method at a Floor Price of Rs. 55/- per share. Arif Habib Limited is serving as the Lead Manager for the issue.
In accordance with Circular No. 16 of 2023, dated November 08, 2023, issued by the Securities & Exchange Commission of Pakistan (SECP), the Draft Prospectus of BF Biosciences Limited has been made available on the PSX website for public comments under the caption “Public Comments on Draft Prospectus of BF Biosciences Limited.”
Investors and interested parties can review the details of the issue through the attached draft of the company’s prospectus available on the PSX website.
BF Biosciences Limited (“BFBL”, “Company”, or the “Issuer”) was incorporated as an unlisted public limitedcompany under the Companies Ordinance, 1984 (now Companies Act, 2017) in 2006, and operates within the pharmaceutical industry. BFBL is a joint venture between Ferozsons Laboratories Limited and the Bagó Group of Argentina.
The Company’s core operations involve the import, manufacturing, marketing and distribution oF pharmaceutical products. BFBL distinguishes itself by producing life-saving medications that are accessible to all.
BF Biosciences Limited has led Pakistan’s emergence in the field of biotech manufacturing. BF Biosciences Limited has propelled Pakistan into the exclusive league of exporters of biotech pharmaceuticals specifically during Covid 19. The Company has a manufacturing facility located at 5 KM – Sunder Raiwind Road, Lahore, featuring a state-of-the-art biotech plant designed and executed by Telstar technologies.
